Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers

被引:148
作者
Curran, S [1 ]
Dundas, SR [1 ]
Buxton, J [1 ]
Leeman, MF [1 ]
Ramsay, R [1 ]
Murray, GI [1 ]
机构
[1] Univ Aberdeen, Dept Pathol, Aberdeen AB25 2ZD, Scotland
关键词
D O I
10.1158/1078-0432.CCR-04-0424
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes involved in tumor invasion; several individual members of which have been implicated in tumor prognosis. These enzymes and their physiologic inhibitors, the tissue inhibitors of matrix metalloproteinases (TIMPs), act in a coordinated manner to form an integrated system. Therefore, to understand their role in tumor invasion, it is necessary to evaluate them collectively. Experimental Design: In this study all of the major members of the matrix metalloproteinase (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MT1-MMP and MT2-MMP)/tissue inhibitor of matrix metalloproteinase (TIMP-1, TIMP-2, and TIMP-3) system have been investigated by immunohistochemistry in a series (n = 90) of stage III (Dukes' C) colorectal cancers. An immunohistochemical score based on the intensity of immunoreactivity and proportion of immunoreactive cells was established for each MMP and TIMP. Results: The MMP/TIMP profile defined by hierarchical cluster analysis of the immunohistochemical score identifies a distinct group of colorectal cancers with poor prognosis (log-rank test, 12.22, P = 0.0005). The median survival time of patients in this survival group was 18 months compared with a median survival of 49 months in the "good" survival group. Multivariate analysis showed that this profile was independently the most significant prognostic factor (P = 0.001). Conclusions: This study has identified that the MMP/TIMP profile is an independent indicator of poor prognosis in colorectal cancer.
引用
收藏
页码:8229 / 8234
页数:6
相关论文
共 24 条
[1]  
Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO
[2]  
2-I
[3]   Metalloproteinase inhibitors: biological actions and therapeutic opportunities [J].
Baker, AH ;
Edwards, DR ;
Murphy, G .
JOURNAL OF CELL SCIENCE, 2002, 115 (19) :3719-3727
[4]   Timeline - Matrix metalloproteinases: a tail of a frog that became a prince [J].
Brinckerhoff, CE ;
Matrisian, LM .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (03) :207-214
[5]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[6]  
Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO
[7]  
2-C
[8]   Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis [J].
Curran, S ;
Murray, GI .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (13) :1621-1630
[9]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[10]   Complex roles of tissue inhibitors of metalloproteinases in cancer [J].
Jiang, YF ;
Goldberg, ID ;
Shi, YE .
ONCOGENE, 2002, 21 (14) :2245-2252